Alpha-lipoic acid: A small German study using 600 mg/day supplementation of ALAstabilized AD for an 11month period. Eight of the nine participants had equal or higher MMSE and ADAScog scores at the end of the trial. Scores of the ninth participant fell below the curve only in the last month. All participants were taking anti-cholinergic drugs at initiation of the trial, and experiencing the expected decline in cognition. ALA abruptly halted that decline. ALA is a capable metal chelator for iron, copper, transition metals and likely aluminum,and a powerful anti-oxidant.